White House Executive Order Sparks Surge in Psychedelic Biotech Stocks

Compass Pathways (NASDAQ: CMPS) saw its valuation skyrocket on Monday after the White House issued an Executive Order designed to fast-track the research and approval of psychedelic drugs. The stock surged more than 50% in early trading, maintaining a gain of 41.2% by midday. The presidential mandate focuses on increasing access to innovative treatments to address the crisis of serious mental illness in the United States. By accelerating research models and drug approval processes, the administration seeks to bring life-saving psychedelic therapies to market more efficiently. Compass Pathways is a primary beneficiary of this shift, as it develops COMP360, a synthetic psilocybin therapy. The company has already reported two positive phase 3 trials for the treatment of treatment-resistant depression (TRD) and is currently coordinating with the FDA for submission. CEO Kabir Nath praised the move, stating that the order aligns regulatory urgency with patient needs without compromising scientific rigor. He noted that the company is already working toward formal approval for its synthetic compound. The market reaction underscores the binary nature of biotechnology investing, where regulatory catalysts can lead to extreme volatility. Investors are now betting on a significantly shorter timeline for the commercialization of synthetic psilocybin treatments.